Business Wire

Xsolla Brings Mobile-First Monetization Expertise to Gamesforum Barcelona 2026, Where Europe's Mobile Gaming Leaders Gather to Solve the Industry's Toughest Growth Challenges

9.2.2026 20:30:00 CET | Business Wire | Press release

Share

Platform That Powers 1,500+ Game Developers Across 200+ Geographies Expands Commerce, Payment, and Distribution Infrastructure to Adjacent Creative Industries

Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced its participation in Gamesforum Barcelona 2026, taking place Feb.10-11 at the InterContinental Hotel in Barcelona. This event brings together Europe's sharpest minds in mobile gaming for practical, data-driven sessions focused on what actually works in today's hypercompetitive mobile landscape.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260209301026/en/

(Graphic: Xsolla)

With over 600 professionals from Europe's top publishers, ad networks, and studios in attendance, Gamesforum Barcelona has earned its reputation as the place where mobile gaming's most pressing problems get solved: How do you scale profitably? How do you retain players in saturated markets? How do you monetize without alienating your audience?

"Gamesforum Barcelona represents everything we value about the European mobile gaming community, it's pragmatic, data-obsessed, and laser-focused on sustainable growth," said Berkley Egenes, Chief Marketing & Growth Officer at Xsolla. "The mobile developers we meet at Gamesforum aren't looking for hype. They're looking for solutions that move the needle on LTV, reduce churn, and give them leverage against platform economics that weren't designed for their success. We've spent years solving these exact problems for hundreds of mobile studios, and we're excited to share what's actually working in 2026."

Xsolla is at the forefront of these important conversations:

  • 700+ Web Shops Launched for Mobile Games: Xsolla doesn't just talk about direct-to-consumer—we've built it at scale. Over 700 mobile game studios have implemented Xsolla's "Pay Online, Play on Device" web shop model, bypassing platform fees, keeping more revenue, and building direct player relationships. This isn't experimental. It's currently in use by studios across Europe, Asia, and the Americas.
  • Global Payments That Actually Convert: Supporting 1,000+ payment methods across 200+ geographies sounds impressive until you realize what it means in practice: players in Poland can pay with Blik, players in Brazil use Pix, players in Southeast Asia use local e-wallets—and your conversion rates stop bleeding. Mobile developers live and die by conversion optimization, and local payment support is where the biggest gains happen.
  • Infrastructure Built for Mobile's Reality: Mobile game studios don't have time to build payment systems, combat fraud, manage compliance across dozens of markets, or navigate platform policies. Xsolla handles the complex, unglamorous backend so developers can focus on what they're actually good at: making games players love and can't stop playing.

The European mobile gaming market is one of the most sophisticated and competitive in the world. Studios here operate on thin margins, with high player expectations and constant pressure to optimize every step of the funnel. Gamesforum Barcelona reflects this reality: it's where monetization teams come to learn from one another, where UA professionals share what drives results, and where product leaders figure out how to build sustainable businesses in an increasingly challenging market.

Xsolla's participation goes beyond a booth presence. The company's team will be on the ground for hands-on conversations about the real challenges mobile studios face: web shop economics, regional payment optimization, platform diversification strategies, and building scalable D2C capabilities. These aren't sales pitches, they're strategy sessions with teams who've been in the trenches.

Mobile game developers, publishers, UA teams, and monetization professionals attending Gamesforum Barcelona 2026 are invited to connect with Xsolla's business development and product specialists to discuss specific challenges, share data on what's working in their markets, and explore how Xsolla's infrastructure can support their growth objectives.

To schedule a meeting with Xsolla during Gamesforum Barcelona, visit: xsolla.pro/gamesforum-barcelona

About Xsolla

Xsolla is a global commerce company with robust tools and services to help developers solve the inherent challenges of the video game industry. From indie to AAA, companies partner with Xsolla to help them fund, distribute, market, and monetize their games. Grounded in the belief in the future of video games, Xsolla is resolute in the mission to bring opportunities together, and continually make new resources available to creators. Headquartered and incorporated in Los Angeles, California, Xsolla operates as the merchant of record and has helped over 1,500+ game developers to reach more players and grow their businesses around the world. With more paths to profits and ways to win, developers have all the things needed to enjoy the game.

For more information, visit xsolla.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20260209301026/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye